| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostate | 41 | 2025 | 413 | 5.020 |
Why?
|
| Prostatic Hyperplasia | 16 | 2025 | 91 | 4.720 |
Why?
|
| Prostatic Neoplasms | 48 | 2023 | 1771 | 3.710 |
Why?
|
| Epithelial Cells | 27 | 2019 | 702 | 2.370 |
Why?
|
| Receptors, Androgen | 14 | 2018 | 120 | 1.860 |
Why?
|
| Cancer-Associated Fibroblasts | 7 | 2021 | 37 | 1.790 |
Why?
|
| Transforming Growth Factor beta | 10 | 2016 | 328 | 1.620 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2016 | 462 | 1.350 |
Why?
|
| Fibroblasts | 13 | 2018 | 767 | 1.340 |
Why?
|
| Stromal Cells | 15 | 2021 | 152 | 1.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2017 | 1310 | 1.060 |
Why?
|
| Mice | 46 | 2022 | 12110 | 0.800 |
Why?
|
| NF-kappa B | 2 | 2016 | 470 | 0.800 |
Why?
|
| Cell Movement | 7 | 2019 | 797 | 0.790 |
Why?
|
| Mesoderm | 8 | 2012 | 124 | 0.780 |
Why?
|
| Prostatitis | 1 | 2022 | 13 | 0.780 |
Why?
|
| Male | 74 | 2025 | 43925 | 0.750 |
Why?
|
| PPAR gamma | 2 | 2012 | 74 | 0.740 |
Why?
|
| Androgens | 8 | 2016 | 176 | 0.730 |
Why?
|
| Carcinoma | 3 | 2017 | 438 | 0.730 |
Why?
|
| Animals | 56 | 2023 | 28003 | 0.710 |
Why?
|
| Cell Differentiation | 15 | 2023 | 1592 | 0.700 |
Why?
|
| Lower Urinary Tract Symptoms | 4 | 2017 | 76 | 0.690 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 252 | 0.660 |
Why?
|
| Mice, SCID | 12 | 2016 | 265 | 0.650 |
Why?
|
| Carcinogenesis | 2 | 2021 | 222 | 0.640 |
Why?
|
| Kallikreins | 2 | 2018 | 46 | 0.630 |
Why?
|
| Myeloid Cells | 1 | 2019 | 106 | 0.630 |
Why?
|
| Cell Line, Tumor | 16 | 2021 | 2669 | 0.620 |
Why?
|
| Imatinib Mesylate | 1 | 2018 | 127 | 0.600 |
Why?
|
| Cell Line | 14 | 2022 | 2505 | 0.600 |
Why?
|
| Prostate-Specific Antigen | 4 | 2018 | 341 | 0.590 |
Why?
|
| Signal Transduction | 15 | 2016 | 3508 | 0.590 |
Why?
|
| Transplantation, Heterologous | 10 | 2010 | 370 | 0.590 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 192 | 0.580 |
Why?
|
| Hyperglycemia | 1 | 2019 | 176 | 0.570 |
Why?
|
| Urothelium | 5 | 2012 | 65 | 0.570 |
Why?
|
| Urinary Bladder | 6 | 2013 | 250 | 0.570 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 174 | 0.550 |
Why?
|
| Cell Separation | 3 | 2015 | 202 | 0.530 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2016 | 13 | 0.530 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2016 | 9 | 0.520 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2016 | 50 | 0.520 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2016 | 12 | 0.520 |
Why?
|
| Pyrimidines | 1 | 2018 | 378 | 0.500 |
Why?
|
| Disease Progression | 15 | 2017 | 1503 | 0.500 |
Why?
|
| Drug Resistance | 1 | 2016 | 235 | 0.490 |
Why?
|
| Humans | 64 | 2025 | 92337 | 0.480 |
Why?
|
| Cell Proliferation | 11 | 2019 | 1720 | 0.480 |
Why?
|
| Rats | 18 | 2023 | 4067 | 0.470 |
Why?
|
| Regeneration | 2 | 2013 | 158 | 0.460 |
Why?
|
| Orchiectomy | 5 | 2016 | 62 | 0.460 |
Why?
|
| Neoplasm Invasiveness | 9 | 2017 | 569 | 0.460 |
Why?
|
| Tumor Microenvironment | 6 | 2021 | 520 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 598 | 0.450 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2023 | 131 | 0.420 |
Why?
|
| Retinoblastoma Protein | 5 | 2010 | 66 | 0.410 |
Why?
|
| Cathepsin D | 1 | 2012 | 5 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 2 | 2012 | 291 | 0.400 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1277 | 0.390 |
Why?
|
| Lipid Metabolism | 3 | 2025 | 213 | 0.390 |
Why?
|
| Lipid Droplets | 3 | 2021 | 19 | 0.380 |
Why?
|
| Stem Cells | 3 | 2010 | 383 | 0.380 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 142 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2016 | 139 | 0.370 |
Why?
|
| Mice, Nude | 12 | 2020 | 828 | 0.360 |
Why?
|
| Models, Biological | 4 | 2012 | 1786 | 0.360 |
Why?
|
| Serpins | 3 | 2019 | 31 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2017 | 502 | 0.350 |
Why?
|
| Nerve Growth Factors | 3 | 2019 | 61 | 0.350 |
Why?
|
| Genetic Heterogeneity | 2 | 2021 | 68 | 0.350 |
Why?
|
| Epithelium | 5 | 2021 | 324 | 0.350 |
Why?
|
| Neoplasms | 2 | 2020 | 3117 | 0.340 |
Why?
|
| Diacylglycerol O-Acyltransferase | 2 | 2021 | 4 | 0.340 |
Why?
|
| Endoderm | 1 | 2010 | 24 | 0.330 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 1235 | 0.330 |
Why?
|
| Eye Proteins | 3 | 2019 | 129 | 0.320 |
Why?
|
| Breast Neoplasms | 4 | 2017 | 3053 | 0.320 |
Why?
|
| Membrane Proteins | 5 | 2019 | 1240 | 0.320 |
Why?
|
| Microtubule-Organizing Center | 2 | 2019 | 5 | 0.310 |
Why?
|
| Up-Regulation | 6 | 2016 | 731 | 0.310 |
Why?
|
| Disease Models, Animal | 7 | 2011 | 2448 | 0.310 |
Why?
|
| RNA, Messenger | 8 | 2019 | 2037 | 0.300 |
Why?
|
| Neoplasm Transplantation | 4 | 2015 | 398 | 0.290 |
Why?
|
| Hyperplasia | 2 | 2022 | 152 | 0.290 |
Why?
|
| Cyclin D1 | 1 | 2007 | 84 | 0.280 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 22 | 0.280 |
Why?
|
| Cell Communication | 3 | 2017 | 205 | 0.270 |
Why?
|
| Paracrine Communication | 4 | 2012 | 33 | 0.270 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 47 | 0.270 |
Why?
|
| Recombination, Genetic | 3 | 2005 | 442 | 0.260 |
Why?
|
| Cells, Cultured | 10 | 2017 | 2902 | 0.260 |
Why?
|
| Chemokine CXCL12 | 3 | 2019 | 38 | 0.260 |
Why?
|
| Testosterone | 3 | 2016 | 273 | 0.250 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2019 | 19 | 0.250 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 1191 | 0.240 |
Why?
|
| Mice, Transgenic | 8 | 2015 | 1589 | 0.240 |
Why?
|
| Interleukin-6 | 2 | 2017 | 272 | 0.230 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2017 | 160 | 0.230 |
Why?
|
| Apoptosis | 4 | 2016 | 1743 | 0.230 |
Why?
|
| Lipase | 2 | 2021 | 21 | 0.220 |
Why?
|
| Cell Survival | 4 | 2015 | 1008 | 0.210 |
Why?
|
| Molecular Biology | 1 | 2003 | 90 | 0.190 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 1807 | 0.190 |
Why?
|
| Inflammation | 2 | 2022 | 1025 | 0.190 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 1071 | 0.180 |
Why?
|
| Receptor, EphB2 | 1 | 2021 | 3 | 0.180 |
Why?
|
| Macrophages | 1 | 2025 | 599 | 0.180 |
Why?
|
| Cytokines | 2 | 2019 | 843 | 0.180 |
Why?
|
| Cell Transdifferentiation | 2 | 2012 | 11 | 0.180 |
Why?
|
| Cell Growth Processes | 2 | 2019 | 85 | 0.180 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 4 | 2015 | 9 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2014 | 891 | 0.170 |
Why?
|
| Transcription Factors | 6 | 2012 | 1684 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 247 | 0.170 |
Why?
|
| NADPH Oxidase 4 | 1 | 2020 | 15 | 0.170 |
Why?
|
| THP-1 Cells | 1 | 2019 | 6 | 0.170 |
Why?
|
| Coculture Techniques | 3 | 2017 | 176 | 0.160 |
Why?
|
| HEK293 Cells | 2 | 2019 | 666 | 0.160 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 48 | 0.160 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2019 | 21 | 0.160 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 1576 | 0.150 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 206 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2012 | 187 | 0.150 |
Why?
|
| Testis | 1 | 2019 | 152 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 250 | 0.150 |
Why?
|
| Autoantigens | 1 | 2019 | 134 | 0.150 |
Why?
|
| Transfection | 5 | 2017 | 901 | 0.140 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 174 | 0.140 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2017 | 21 | 0.140 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2017 | 52 | 0.140 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 52 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 505 | 0.140 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 46 | 0.140 |
Why?
|
| Fibronectins | 1 | 2017 | 102 | 0.140 |
Why?
|
| Cell Lineage | 2 | 2021 | 302 | 0.130 |
Why?
|
| Mice, Knockout | 7 | 2015 | 2087 | 0.130 |
Why?
|
| Aged | 7 | 2025 | 19943 | 0.130 |
Why?
|
| NFI Transcription Factors | 1 | 2015 | 7 | 0.130 |
Why?
|
| Fetus | 1 | 2017 | 234 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 250 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 624 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 65 | 0.120 |
Why?
|
| Homeodomain Proteins | 3 | 2012 | 561 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2015 | 704 | 0.120 |
Why?
|
| Base Sequence | 3 | 2017 | 2317 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2016 | 289 | 0.120 |
Why?
|
| Antigens, CD | 2 | 2015 | 473 | 0.120 |
Why?
|
| Isoenzymes | 1 | 2016 | 277 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2010 | 680 | 0.120 |
Why?
|
| Polycomb-Group Proteins | 1 | 2015 | 9 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 4 | 2017 | 1052 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 189 | 0.120 |
Why?
|
| Gene Expression | 2 | 2016 | 1312 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 47 | 0.120 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2015 | 82 | 0.120 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 109 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 118 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 383 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2020 | 725 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 6 | 2012 | 3360 | 0.110 |
Why?
|
| Fetal Proteins | 1 | 2014 | 18 | 0.110 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2014 | 30 | 0.110 |
Why?
|
| Transcription Factor AP-1 | 1 | 2014 | 65 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 1477 | 0.110 |
Why?
|
| E2F Transcription Factors | 2 | 2010 | 19 | 0.100 |
Why?
|
| Pregnancy | 4 | 2020 | 3110 | 0.100 |
Why?
|
| Tissue Engineering | 2 | 2013 | 201 | 0.100 |
Why?
|
| Metaplasia | 1 | 2012 | 37 | 0.100 |
Why?
|
| Cellular Reprogramming | 1 | 2013 | 45 | 0.100 |
Why?
|
| Blotting, Western | 3 | 2010 | 795 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2015 | 367 | 0.100 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2012 | 5 | 0.100 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 37 | 0.100 |
Why?
|
| Bone and Bones | 1 | 2014 | 280 | 0.100 |
Why?
|
| Genome, Human | 1 | 2017 | 799 | 0.100 |
Why?
|
| Ureter | 1 | 2013 | 96 | 0.100 |
Why?
|
| Phenotype | 4 | 2006 | 2498 | 0.090 |
Why?
|
| Cell Division | 4 | 2006 | 701 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2008 | 46 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 343 | 0.090 |
Why?
|
| Telomerase | 2 | 2008 | 68 | 0.090 |
Why?
|
| Genes, Retinoblastoma | 1 | 2010 | 21 | 0.090 |
Why?
|
| Homeostasis | 2 | 2012 | 450 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 561 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 224 | 0.090 |
Why?
|
| Wnt Proteins | 2 | 2008 | 130 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 1392 | 0.090 |
Why?
|
| Culture Media, Conditioned | 2 | 2008 | 103 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2011 | 107 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 530 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 2394 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2013 | 668 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1723 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 1247 | 0.080 |
Why?
|
| Lipogenesis | 2 | 2019 | 25 | 0.080 |
Why?
|
| Polyploidy | 1 | 2008 | 18 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2008 | 10 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 4 | 2017 | 968 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 190 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2008 | 4 | 0.070 |
Why?
|
| Mammary Glands, Human | 1 | 2008 | 24 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 698 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3017 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 105 | 0.070 |
Why?
|
| Cellular Senescence | 1 | 2008 | 104 | 0.070 |
Why?
|
| Middle Aged | 5 | 2025 | 27030 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 123 | 0.070 |
Why?
|
| Female | 9 | 2017 | 47893 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2007 | 283 | 0.070 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 82 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2008 | 523 | 0.070 |
Why?
|
| Transplantation, Heterotopic | 1 | 2005 | 48 | 0.060 |
Why?
|
| Hybridization, Genetic | 1 | 2006 | 106 | 0.060 |
Why?
|
| RNA | 1 | 2009 | 589 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 36 | 0.060 |
Why?
|
| Estradiol | 1 | 2006 | 250 | 0.060 |
Why?
|
| Retroviridae | 1 | 2005 | 76 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 2025 | 50 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2005 | 152 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 307 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2025 | 142 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 282 | 0.060 |
Why?
|
| Organ Size | 1 | 2025 | 375 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 221 | 0.050 |
Why?
|
| Urogenital System | 1 | 2023 | 10 | 0.050 |
Why?
|
| Zinc | 1 | 2004 | 100 | 0.050 |
Why?
|
| Rodentia | 1 | 2023 | 42 | 0.050 |
Why?
|
| Chimera | 1 | 2003 | 54 | 0.050 |
Why?
|
| Organoids | 1 | 2023 | 70 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1212 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 81 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 403 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2004 | 131 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 323 | 0.050 |
Why?
|
| Integrases | 2 | 2014 | 63 | 0.050 |
Why?
|
| Gene Regulatory Networks | 2 | 2015 | 315 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2015 | 431 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 441 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 874 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 734 | 0.040 |
Why?
|
| Mutation | 2 | 2009 | 4204 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 429 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 117 | 0.040 |
Why?
|
| Time Factors | 3 | 2017 | 5430 | 0.040 |
Why?
|
| Microtubules | 1 | 2019 | 129 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 501 | 0.040 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2017 | 5 | 0.040 |
Why?
|
| Integrin alpha5beta1 | 1 | 2017 | 13 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2017 | 12 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 390 | 0.040 |
Why?
|
| Triglycerides | 1 | 2018 | 234 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 299 | 0.040 |
Why?
|
| Lipids | 1 | 2019 | 278 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 128 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 81 | 0.030 |
Why?
|
| Laminin | 2 | 2009 | 93 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2009 | 206 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 384 | 0.030 |
Why?
|
| Proteoglycans | 2 | 2009 | 126 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 39 | 0.030 |
Why?
|
| Proteome | 1 | 2017 | 149 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2007 | 313 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 2004 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 138 | 0.030 |
Why?
|
| Fluorometholone | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2015 | 6 | 0.030 |
Why?
|
| Triamcinolone | 1 | 2015 | 20 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 88 | 0.030 |
Why?
|
| Collagen | 2 | 2009 | 303 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 32 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2015 | 39 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 60 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 101 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2014 | 39 | 0.030 |
Why?
|
| ADAM17 Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2014 | 11 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 200 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 165 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2014 | 30 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 514 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 314 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 164 | 0.030 |
Why?
|
| Uroplakins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2013 | 16 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2013 | 21 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1513 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 347 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1756 | 0.030 |
Why?
|
| Adult | 1 | 2012 | 27532 | 0.030 |
Why?
|
| Receptor, Notch2 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 102 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 111 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2012 | 65 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 57 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 119 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2012 | 139 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2011 | 79 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 538 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 741 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2978 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 379 | 0.020 |
Why?
|
| Urethra | 1 | 2010 | 114 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 1130 | 0.020 |
Why?
|
| Chromones | 1 | 2009 | 31 | 0.020 |
Why?
|
| Culture Techniques | 1 | 2009 | 89 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 531 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2009 | 47 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2447 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 699 | 0.020 |
Why?
|
| Morpholines | 1 | 2009 | 72 | 0.020 |
Why?
|
| Cyclin D | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 25 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 33 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 82 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 141 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 276 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2008 | 84 | 0.020 |
Why?
|
| Computational Biology | 1 | 2011 | 566 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1163 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 1141 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2007 | 6 | 0.020 |
Why?
|
| Uroplakin III | 1 | 2006 | 3 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 305 | 0.020 |
Why?
|
| Kanamycin Kinase | 1 | 2006 | 2 | 0.020 |
Why?
|
| Androgen-Binding Protein | 1 | 2006 | 7 | 0.020 |
Why?
|
| Gene Library | 1 | 2007 | 134 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 1850 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 997 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 652 | 0.020 |
Why?
|
| E2F1 Transcription Factor | 1 | 2005 | 16 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2005 | 73 | 0.010 |
Why?
|
| Genes, myc | 1 | 2005 | 42 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 79 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 99 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2005 | 276 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2004 | 37 | 0.010 |
Why?
|
| Plasma Kallikrein | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cations | 1 | 2004 | 31 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 438 | 0.010 |
Why?
|
| Ions | 1 | 2004 | 76 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 298 | 0.010 |
Why?
|
| beta Catenin | 1 | 2005 | 266 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 498 | 0.010 |
Why?
|
| Morphogenesis | 1 | 2005 | 207 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 195 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 698 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 22 | 0.010 |
Why?
|
| Cyclin E | 1 | 2002 | 28 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 67 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 241 | 0.010 |
Why?
|
| Karyotyping | 1 | 2002 | 252 | 0.010 |
Why?
|
| Inbreeding | 1 | 2002 | 45 | 0.010 |
Why?
|
| Homozygote | 1 | 2002 | 201 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 231 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 1108 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 401 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 154 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2002 | 180 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 351 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 684 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 515 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 1939 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 1550 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 1863 | 0.010 |
Why?
|